(Q55463683)

12 July 2018

title

Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma. (English)

1 reference

12 July 2018

0 references

1 reference

1 reference

Dolly G Aguilera

1

1 reference

12 July 2018

Steward Goldman

series ordinal

2

1 reference

12 July 2018

Jason Fangusaro

series ordinal

3

1 reference

12 July 2018

publication date

1 March 2011

1 reference

12 July 2018

published in

Pediatric Blood Cancer

1 reference

12 July 2018

volume

56

1 reference

12 July 2018

issue

3

1 reference

12 July 2018

page(s)

491-494

1 reference

12 July 2018

Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

cites work

1 reference

Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial

21 January 2018

1 reference

High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma.

21 January 2018

1 reference

Role of high-dose chemotherapy for recurrent medulloblastoma and other CNS primitive neuroectodermal tumors

21 January 2018

1 reference

FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma

21 January 2018

1 reference

FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

A perivascular niche for brain tumor stem cells

21 January 2018

1 reference

Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer

21 January 2018

1 reference

Novel anti-angiogenic therapies for malignant gliomas

21 January 2018

1 reference

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma

21 January 2018

1 reference

Angiogenic profile of childhood primitive neuroectodermal brain tumours/medulloblastomas.

21 January 2018

1 reference

Prognostic significance of anaplasia and angiogenesis in childhood medulloblastoma: a pediatric oncology group study.

21 January 2018

1 reference

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study

21 January 2018

1 reference

Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan

21 January 2018

1 reference

Antiangiogenic therapy in the treatment of recurrent medulloblastoma in the adult: case report and review of the literature

21 January 2018

1 reference

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

21 January 2018

1 reference

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

21 January 2018

1 reference

Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.22868

1 reference

12 July 2018

1 reference

12 July 2018